CO5700723A2 - Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca - Google Patents

Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca

Info

Publication number
CO5700723A2
CO5700723A2 CO05017675A CO05017675A CO5700723A2 CO 5700723 A2 CO5700723 A2 CO 5700723A2 CO 05017675 A CO05017675 A CO 05017675A CO 05017675 A CO05017675 A CO 05017675A CO 5700723 A2 CO5700723 A2 CO 5700723A2
Authority
CO
Colombia
Prior art keywords
pharmaceutically acceptable
treat
acceptable salts
amine derivative
cyclic amine
Prior art date
Application number
CO05017675A
Other languages
English (en)
Spanish (es)
Inventor
Brian Guth
Seidler Randolph
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29265956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5700723(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of CO5700723A2 publication Critical patent/CO5700723A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO05017675A 2002-07-25 2005-02-24 Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca CO5700723A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02016602A EP1362590B1 (en) 2002-07-25 2002-07-25 Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

Publications (1)

Publication Number Publication Date
CO5700723A2 true CO5700723A2 (es) 2006-11-30

Family

ID=29265956

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05017675A CO5700723A2 (es) 2002-07-25 2005-02-24 Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca

Country Status (29)

Country Link
US (1) US20130317008A1 (enExample)
EP (2) EP1362590B1 (enExample)
JP (3) JP2005533853A (enExample)
KR (1) KR20050074432A (enExample)
CN (1) CN100502874C (enExample)
AR (1) AR040690A1 (enExample)
AT (2) ATE257384T1 (enExample)
AU (1) AU2003254554B8 (enExample)
BR (1) BR0312852A (enExample)
CA (1) CA2493208C (enExample)
CO (1) CO5700723A2 (enExample)
CY (1) CY1112173T1 (enExample)
DE (1) DE60200160T2 (enExample)
DK (2) DK1362590T3 (enExample)
ES (2) ES2211846T3 (enExample)
HR (1) HRP20050075B1 (enExample)
MX (1) MXPA05000617A (enExample)
MY (1) MY128529A (enExample)
NZ (1) NZ538424A (enExample)
PE (1) PE20040706A1 (enExample)
PL (1) PL214716B1 (enExample)
PT (2) PT1362590E (enExample)
SA (1) SA03240350B1 (enExample)
SI (2) SI1362590T1 (enExample)
TR (1) TR200400127T4 (enExample)
TW (1) TWI319321B (enExample)
UY (1) UY27910A1 (enExample)
WO (1) WO2004011006A1 (enExample)
ZA (1) ZA200500084B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
EP1362590B1 (en) * 2002-07-25 2004-01-07 Boehringer Ingelheim Pharma GmbH & Co.KG Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
CA2617519A1 (en) * 2005-08-23 2007-03-01 Astellas Pharma Inc. Agent for treating atrial fibrillation
EP1762179A1 (en) 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2927538B1 (fr) 2008-02-14 2010-02-19 Servier Lab Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant.
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
EP2741735A1 (en) 2011-08-12 2014-06-18 Boehringer Ingelheim Vetmedica GmbH Funny current (if) inhibitors for use in a method of treating and preventing heart failure in feline
WO2014122248A1 (en) 2013-02-11 2014-08-14 Boehringer Ingelheim Vetmedica Gmbh Kit-of-parts

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
DE3541811A1 (de) * 1985-11-27 1987-06-04 Thomae Gmbh Dr K Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3736866A1 (de) * 1987-10-30 1989-05-11 Thomae Gmbh Dr K Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
DE3805635A1 (de) * 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
JP4240173B2 (ja) * 1998-06-03 2009-03-18 日産化学工業株式会社 インダン誘導体
PT1186601E (pt) * 1999-06-03 2004-06-30 Yamanouchi Pharma Co Ltd Novos derivados de isoquinolina ou seus sais
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
EP1362590B1 (en) * 2002-07-25 2004-01-07 Boehringer Ingelheim Pharma GmbH & Co.KG Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

Also Published As

Publication number Publication date
AU2003254554A1 (en) 2004-02-16
AR040690A1 (es) 2005-04-13
CN100502874C (zh) 2009-06-24
TWI319321B (en) 2010-01-11
MXPA05000617A (es) 2005-08-19
TR200400127T4 (tr) 2004-02-23
PT1362590E (pt) 2004-05-31
MY128529A (en) 2007-02-28
DK1362590T3 (da) 2004-03-29
ES2211846T3 (es) 2004-07-16
TW200412974A (en) 2004-08-01
ATE257384T1 (de) 2004-01-15
JP2005533853A (ja) 2005-11-10
EP1362590A8 (en) 2004-02-25
ES2367109T3 (es) 2011-10-28
PL214716B1 (pl) 2013-09-30
AU2003254554B8 (en) 2009-02-26
CY1112173T1 (el) 2015-12-09
CN1671392A (zh) 2005-09-21
ATE510543T1 (de) 2011-06-15
BR0312852A (pt) 2005-04-19
UY27910A1 (es) 2004-02-27
PL372993A1 (en) 2005-08-08
JP2009256379A (ja) 2009-11-05
SA03240350B1 (ar) 2007-10-29
DE60200160D1 (de) 2004-02-12
CA2493208A1 (en) 2004-02-05
AU2003254554B2 (en) 2009-01-29
HRP20050075A2 (en) 2005-12-31
SI1362590T1 (sl) 2004-04-30
PT1534296E (pt) 2011-08-18
HRP20050075B1 (hr) 2013-12-20
CA2493208C (en) 2011-11-01
WO2004011006A1 (en) 2004-02-05
EP1534296A1 (en) 2005-06-01
NZ538424A (en) 2006-10-27
DE60200160T2 (de) 2004-11-04
PE20040706A1 (es) 2004-12-06
SI1534296T1 (sl) 2011-09-30
EP1534296B1 (en) 2011-05-25
ZA200500084B (en) 2005-10-26
KR20050074432A (ko) 2005-07-18
JP2013166781A (ja) 2013-08-29
DK1534296T3 (da) 2011-08-15
US20130317008A1 (en) 2013-11-28
EP1362590A1 (en) 2003-11-19
EP1362590B1 (en) 2004-01-07

Similar Documents

Publication Publication Date Title
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
ES2175127T3 (es) Derivados de la quinazolina y su uso.
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
UY27740A1 (es) Nuevos compuestos
ECSP066365A (es) Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk
ECSP055738A (es) PROCESO ENANTIOSELECTIVO PARA LA PREPARACIÓN DE AMBOS ENANTIÓMEROS DE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ-[b,f]-AZEPIN-5-CARBOXAMIDA Y SUS NUEVAS FORMAS DE CRISTAL
CR7820A (es) Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos
AR058433A1 (es) Derivado de 1,1-dioxido de 1,4-benzotiazepina ,procedimiento para su preparacion ,medicamentos que comprenden este compuesto y su uso
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
UY25242A1 (es) Inhibidores de benzotiazol de la proteína tirosina cinasa
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
AR039633A2 (es) Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
AR019145A1 (es) Proceso para aplicar un estrato a una unidad farmaceutica, forma de dosis de unidad, y aparato para estratificar una unidad farmaceutica.
CR20190144A (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
UY26422A1 (es) Método para administrar un inhibidor de fosfodiesterasa 4
ES2422286T3 (es) Uso de apamina para tratar la enfermedad de Parkinson
ES2563068T3 (es) Tratamiento de esclerosis múltiple (MS) con Campath-1H
AR062784A1 (es) Tratmiento de los vertigos con acetil -l- leucina
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
AR029666A1 (es) Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina
UY30557A1 (es) Tratamiento y prevencion de la fibrosis intestinal

Legal Events

Date Code Title Description
FC Application refused